Collagen Solutions PLC Board Appointments (4915Z)

TIDMCOS

RNS Number : 4915Z

Collagen Solutions PLC

03 September 2018

Collagen Solutions Plc

(the "Company" or the "Group")

Board Appointments

Delivering on our growth strategy

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces the appointment of Tom Hyland, Chief Operating Officer, and Lou Ruggiero, Chief Business Officer, to the Board with immediate effect.

Tom Hyland (53), Chief Operating Officer, joined Collagen Solutions in 2014 bringing experience in the field of collagen chemistry and the development, manufacturing, validation and engineering requirements of collagen-based medical devices. Tom has been involved in bringing a number of collagen-based products to market and has most recently provided oversight of the Company's development business and the reconfiguring the Company's Glasgow operation. Tom has previously worked with a number of global life science companies including Johnson and Johnson Medical, Microsulis, Intercell Biomedical, Alere Technologies and Invitrogen.

Lou Ruggiero (58), joined the Company in April 2018 as Chief Business Officer to focus on speed of delivery and execution within the commercial arena. Lou has previously held a number of commercial roles in sales and general management in the healthcare and technology industries. Prior to joining Collagen Solutions, Lou served as Senior Vice President of Sales at Pearson Clinical Assessments and as Chief Commercial Officer of Hely & Weber Orthopedics. Prior to this he was Vice President of Sales and Business Development at Ossur Americas. Previously, Lou spent ten years as a senior executive and Board Director in the orthopaedic device industry.

On appointment Tom Hyland will be granted options over 1,500,000 ordinary shares of 1 pence each in the share capital of the Company exercisable on the market price applicable on the appointment date with vesting conditions dependent on achieving a closing middle market price per Share of 10 pence at any time after the date of grant and on the Company delivering sustainable positive cash flows from operations (sustained for a period of at least six consecutive monthly periods).

David Evans, Chairman of Collagen Solutions, said: "We are delighted that Lou and Tom are joining the Board. Between them they have a wealth of experience which we believe will help us deliver on our strategic goals and take us to the next level of growth."

 
 Tom Hyland 
 Current Directorships             Previous Directorships 
                                  ----------------------- 
 
   Hyland Enterprise and Housing     None 
   Limited 
   Collagen Solution(UK) Limited 
                                  ----------------------- 
 

Tom Hyland holds 157,859 ordinary shares in the capital of the Company.

 
 Lou Ruggiero 
 Current Directorships   Previous Directorships 
                        ---------------------------------------- 
 
   None                    Instant Bioscan, Tucson, Arizona 
                           Stardust Building Supplies, Phoenix, 
                           Arizona 
                           Grangecroft Consulting, LLC, Phoenix, 
                           Arizona OneSource Medical, LLC, 
                           Phoenix, Arizona 
                        ---------------------------------------- 
 

Lou Ruggiero holds no ordinary shares in the capital of the Company.

Enquiries:

 
 Collagen Solutions Plc 
 Jamal Rushdy, CEO                                                     Via Walbrook 
 Hilary Spence, CFO 
 
 Cenkos Securities Plc (Nominated 
  Adviser and Broker) 
 Steve Cox (Corporate Finance)                                   Tel: [phone] 
 Stephen Keys 
 
 Walbrook PR Ltd                      Tel: [phone] or [e-mail] 
 Anna Dunphy                                                     Mob: [phone] 
 Helen Cresswell                                                 Mob: [phone] 
 
 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For more information go to: www.collagensolutions.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOADLLFBVKFZBBF

(END) Dow Jones Newswires

September 03, 2018 02:00 ET (06:00 GMT)